PT-141
$69.99
PT-141
Bremelanotide and sexual-desire signaling
Identity: cyclic melanocortin receptor agonist.
Approved Vyleesi use: defined acquired, generalized low-desire disorder.
Clinical population: premenopausal women meeting the indication criteria.
Description
PT-141 – 10mg
Mechanism: engages melanocortin signaling associated with sexual desire.
Drug distinction: differs from sildenafil, which inhibits the PDE5 enzyme.
Human findings: improved desire scores and reduced associated distress.
Common effects: nausea, flushing and headache; pigmentation can persist.
Interaction: slowed stomach emptying can reduce oral naltrexone and other
drug absorption.
Cardiovascular effects: transient BP rise; contraindicated with uncontrolled
hypertension or known CV disease.
Reviews
There are no reviews yet.